Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo

Bone

Volumn 37, Issue 3, 2005, Pages 349-358

  Coxon, Fraser P ^a   Ebetino, Frank H ^b   Mules, Emilie H ^c   Seabra, Miguel C ^c   McKenna, Charles E ^d   Rogers, Michael J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bisphosphonate; Osteoclast; Phosphonocarboxylate; Protein prenylation; Rab GGTase

Indexed keywords

2 (2 PYRIDINYL) 1 ETHYLIDENE 1,1 PHOSPHONOCARBOXYLIC ACID; 2 (3 PYRIDINYL) 1 ETHYLIDENE 1,1 PHOSPHONOCARBOXYLIC ACID; 2 (3 PYRIDINYL) 1 HYDROXYETHYLIDENE 1,1 PHOSPHONOCARBOXYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; ENZYME INHIBITOR; GERANYLTRANSFERASE; HYDROXYL GROUP; NE 10790; NITROGEN; RAB PROTEIN; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BONE MARROW CELL; BONE MINERAL; CELL LINE; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRENYLATION; PROTEIN FAMILY; PROTEIN LOCALIZATION; RABBIT; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BONE DENSITY; BONE RESORPTION; CELL MEMBRANE; CELLS, CULTURED; CYTOSOL; ENZYME INHIBITORS; HYDROXYLATION; MICE; MOLECULAR STRUCTURE; ORGANOPHOSPHORUS COMPOUNDS; OSTEOCLASTS; PROTEIN ISOPRENYLATION; PYRIDINES; RABBITS;

EID: 23844443254     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.04.021     Document Type: Article

References (38)

1. M.C. Seabra Membrane association and targeting of prenylated Ras-like GTPases Cell. Signal. 10 1998 167 172
2. P.J. Casey, and M.C. Seabra Protein prenyltransferases J. Biol. Chem. 271 1996 5289 5292
3. M. Zerial, and H. McBride Rab proteins as membrane organizers Nat. Rev. Mol. Cell Biol. 2 2001 107 117
4. F.P. Coxon, M.H. Helfrich, B. Larijani, M. Muzylak, J.E. Dunford, and D. Marshall Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages J. Biol. Chem. 276 2001 48213 48222
5. R.G. Russell, and M.J. Rogers Bisphosphonates: from the laboratory to the clinic and back again Bone 25 1999 97 106
6. M.J. Rogers New insights into the molecular mechanisms of action of bisphosphonates Curr. Pharm. Des. 9 2003 2643 2658
7. M. Sato, W. Grasser, N. Endo, R. Akins, H. Simmons, and D.D. Thompson Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J. Clin. Invest. 88 1991 2095 2105
8. P. Masarachia, M. Weinreb, R. Balena, and G.A. Rodan Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones Bone 19 1996 281 290
9. J.D. Bergstrom, R.G. Bostedor, P.J. Masarachia, A.A. Reszka, and G. Rodan Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase Arch. Biochem. Biophys. 373 2000 231 241
10. J.E. Dunford, K. Thompson, F.P. Coxon, S.P. Luckman, F.M. Hahn, and C.D. Poulter Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J. Pharmacol. Exp. Ther. 296 2001 235 242
11. E. van Beek, C. Lowik, G. van der Pluijm, and S. Papapoulos The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates J. Bone Miner. Res. 14 1999 722 729
12. J.E. Fisher, M.J. Rogers, J.M. Halasy, S.P. Luckman, D.E. Hughes, and P.J. Masarachia Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proc. Natl. Acad. Sci. U. S. A. 96 1999 133 138
13. F.P. Coxon, M.H. Helfrich, R. Van't Hof, S. Sebti, S.H. Ralston, and A. Hamilton Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298 J. Bone Miner. Res. 15 2000 1467 1476
14. E.R. van Beek, C.W. Lowik, F.H. Ebetino, and S.E. Papapoulos Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships Bone 23 1998 437 442
15. Ebetino FH, Bayless AV, Ambugey JI, Ibbotsen KJ, Dansereau S, Ebrahiimpour A. Elucidation of a pharmacophore for the bisphosphonate mechanism of antiresorptive activity. Phosphorus, Sulfur, and Silicon 1996; 109-110:217-20.
16. S.P. Luckman, F.P. Coxon, F.H. Ebetino, R.G. Russell, and M.J. Rogers Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages J. Bone Miner. Res. 13 1998 1668 1678
17. A. Ebrahimpour, and M.D. Francis Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies O. Bijvoet H.A. Fleisch R.E. Canfield R.G.G. Russell Bisphosphonates on bones 1995 Elsevier Amsterdam 125 151
18. M.J. Rogers, D.J. Watts, R.G.G. Russell, X. Ji, X. Xiong, and G.M. Blackburn Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum J. Bone Miner. Res. 9 1994 1029 1039
19. M.J. Rogers, X. Xiong, R.J. Brown, D.J. Watts, R.G.G. Russell, and A.V. Bayless Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae Mol. Pharmacol. 47 1995 398 402
20. S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J. Bone Miner. Res. 13 1998 581 589
21. A.N. Hume, L.M. Collinson, A. Rapak, A.Q. Gomes, C.R. Hopkins, and M.C. Seabra Rab27a regulates the peripheral distribution of melanosomes in melanocytes J. Cell Biol. 152 2001 795 808
22. F.P. Coxon, H.L. Benford, R.G. Russell, and M.J. Rogers Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs Mol. Pharmacol. 54 1998 631 638
23. C. Bordier Phase separation of integral membrane proteins in Triton X-114 solution J. Biol. Chem. 256 1981 1604 1607
24. Z. Ren, C.E. Elson, and M.N. Gould inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells Biochem. Pharmacol. 54 1997 113 1120
25. M.C. Seabra, Y.K. Ho, and J.S. Anant Deficient geranylgeranylation of Ram/Rab27 in choroideremia J. Biol. Chem. 270 1995 24420 24427
26. J.C. Frith, J. Monkkonen, S. Auriola, H. Monkkonen, and M.J. Rogers The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis Arthritis Rheum. 44 2001 2201 2210 (JID-0370605)
27. S.A. Armstrong, M.S. Brown, J.L. Goldstein, and M.C. Seabra Preparation of recombinant Rab geranylgeranyltransferase and Rab escort proteins Methods Enzymol. 257 1995 30 41
28. A. Staal, J.C. Frith, M.H. French, J. Swartz, T. Gungor, and T.W. Harrity The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity J. Bone Miner. Res. 18 2003 88 96
29. E. van Beek, E. Pieterman, L. Cohen, C. Lowik, and S. Papapoulos Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem. Biophys. Res. Commun. 264 1999 108 111
30. F.P. Coxon, and M.J. Rogers The role of prenylated small GTP-binding proteins in the regulation of osteoclast function Calcif. Tissue Int. 72 2003 80 84
31. E.M. Repko, and W.A. Maltese Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability J. Biol. Chem. 264 1989 9945 9952
32. R. Haklai, M.G. Weisz, G. Elad, A. Paz, D. Marciano, and Y. Egozi Dislodgment and accelerated degradation of Ras Biochemistry 37 1998 1306 1314
33. S.A. Holstein, C.L. Wohlford-Lenane, and R.J. Hohl Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB J. Biol. Chem. 277 2002 10678 10682
34. S.G. Senaratne, J.L. Mansi, and K.W. Colston The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells Br. J. Cancer 86 2002 1479 1486
35. C. Denoyelle, L. Hong, J.P. Vannier, J. Soria, C. Soria, and S.M. Kakonen New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects Br. J. Cancer 88 2003 1631 1640
36. W.K. Sietsema, F.H. Ebetino, A.M. Salvagno, and J.A. Bevan Antiresorptive dose-response relationships across three generations of bisphosphonates Drugs Exp. Clin. Res. 15 1989 389 396
37. G. Stenbeck, and M.A. Horton A new specialized cell-matrix interaction in actively resorbing osteoclasts J. Cell Sci. 113 2000 1577 1587
38. M.J. Rogers, S. Gordon, H.L. Benford, F.P. Coxon, S.P. Luckman, and J. Monkkonen Cellular and molecular mechanisms of action of bisphosphonates Cancer 88 2000 2961 2978